Clinical Specialties & Body Systems

Deep dives by specialty—organs, systems, and diseases managed by expert teams.

  • 16 Subtopics
  • 5 Tracked terms
  • Last 30 days Feed window
Search within this topic Ask AI about this topic All topics

Inside Clinical Specialties & Body Systems

Cardiology & Metabolic Health Heart disease, hypertension, lipids, diabetes, and metabolic syndrome. Oncology & Hematology Cancer prevention, screening, therapies, survivorship, and blood disorders. Neurology & Neuroscience Stroke, migraine, epilepsy, neurodegeneration, and movement disorders. Orthopedics & Sports Medicine Bones, joints, tendons; injuries, imaging, and surgical/rehab options. Respiratory & Pulmonology Asthma, COPD, sleep apnea, infections, and environmental lung risks. Gastroenterology & Hepatology Gut health, IBD/IBS, reflux, liver disease, and microbiome research. Endocrinology & Hormones Thyroid, adrenal, reproductive hormones, and metabolic disorders of glands. Nephrology & Urology Kidneys, dialysis, stones, infections, prostate, and continence concerns. Dermatology Skin cancer checks, eczema/psoriasis, acne care, and cosmetic dermatology news. Rheumatology & Autoimmune Arthritis, lupus, vasculitis, biologics, and immune‑modulating therapies. OB‑GYN (Women’s Health) Reproductive health, pregnancy, menopause, and gynecologic care advances. Pediatrics & Adolescent Health Well‑child care, vaccinations, development, and school health issues. Geriatrics & Healthy Aging Falls, cognition, polypharmacy, frailty, and independence strategies. Ophthalmology & Vision Glaucoma, cataracts, macular degeneration, and eye‑care technology updates. ENT (Ear, Nose & Throat) Hearing loss, sinus and allergy care, voice, and sleep‑related airway issues. Dentistry & Oral Health Preventive dentistry, periodontal disease, orthodontics, and oral surgery care.

What this topic collects on

An article joins this feed when it matches these terms. Each one is also a search of its own.

Latest in Clinical Specialties & Body Systems

BBC
bbc.co.uk > programmes > l0058vch

BBC News - New Treatment Gives Hope to People with Ovarian Cancer

21+ hour, 28+ min ago   (59+ words) The former nurse, who was told her stage four ovarian cancer was inoperable, is now cancer-free, thanks to a pioneering new treatment developed in Southampton. New Treatment Gives Hope to People with Ovarian Cancer The former nurse, who was told…...

Medium
medium.com > @eabensonresearchcentre > how-to-do-better-research-a-practical-guide-for-medical-and-community-medicine-researchers-f7da06985445

How to Do Better Research: A Practical Guide for Medical and Community Medicine Researchers

2+ hour, 16+ min ago   (1192+ words) From a Good Research Question to Meaningful Evidence By Dr. Shamin Eabenson, MBBS, MD Community …...

The National Law Review
natlawreview.com > press-releases > enhertur-demonstrated-median-progression-free-survival-143-months-first-line

Enhertu® Demonstrated a Median Progression-Free Survival of 14.3 Months as First-Line Therapy in Patients with HER2 Mutant Advanced Non-Small Cell Lung Cancer in DESTINY-Lung04 Phase 3 Trial

10+ hour, 51+ min ago   (848+ words) Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). In the primary endpoint analysis, Enhertu monotherapy significantly reduced…...

BBC News
bbc.com > news > articles > cgrvq58e1yeo

Lancashire cancer clinicians take on 140-mile charity bike ride

4+ hour, 44+ min ago   (639+ words) Cancer clinicians from Lancashire Teaching Hospitals are set to cycle more than 140 miles across Lancashire and Cumbria to raise funds for charity and promote a programme helping patients prepare for treatment. About 20 members of staff are due to set off…...

Mirage News
miragenews.com > enhertu-shows-14-3-month-pfs-in-her2-lung-1743475

Enhertu Shows 14.3-Month PFS in HER2+ Lung Cancer Trial

9+ hour, 6+ min ago   (338+ words) Results were presented today during the Presidential Symposium at the IASLC 2026 World Conference on Lung Cancer (#WCLC26) hosted by the International Association for the Study of Lung Cancer in Seoul, South Korea (abstract #PL03.08). In the primary endpoint of PFS, Enhertu monotherapy…...

European Medical Journal
emjreviews.com > oncology > article > interview-felix-guerrero-ramos

Félix Guerrero-Ramos on Bladder Cancer Advances

1+ week, 2+ day ago   (653+ words) EMJ This site is intended for healthcare professionals Félix Guerrero-Ramos on Bladder Cancer Advances Félix Guerrero-Ramos | Oncologic Urology Unit Coordinator, Department of Urology, Hospital Universitario 12 de Octubre, Madrid; Co-founder, Danae Urogenomics, Madrid, Spain What first drew you to uro-oncology and,…...

BiotechDispatch
biotechdispatch.com.au > news > noxopharm-moves-lupus-skin-therapy-toward-next-human-trial

Noxopharm moves lupus skin therapy toward next human trial

9+ hour, 29+ min ago   (292+ words) Noxopharm has announced that its lead experimental therapy, SOF-SKN, will advance to an extension clinical study in patients with cutaneous lupus erythematosus, a painful and disfiguring skin condition for which no targeted treatment currently exists. The Sydney-based company said the…...

MarketScreener
marketscreener.com > news > otsuka-arm-s-lung-cancer-drug-plus-chemotherapy-trial-shows-six-month-median-pfs-benefit-ce785bdcd88cf32d

Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit

9+ hour, 20+ min ago   (41+ words) marketscreener.com Otsuka Holdings Co., Ltd. Otsuka Arm's Lung Cancer Drug Plus Chemotherapy Trial Shows Six-Month Median PFS Benefit Published on 09/14/2026 at 01:08 am EDT...

The Asia Business Daily
asiae.co.kr > en > article > bio-health > 2026091413410388821

Yuhan Corporation Unveils Clinical Trial for Oral HER2-Targeted Therapy...Potential Efficacy for Brain Metastases Expected

9+ hour, 47+ min ago   (456+ words) Published 14 Sep.2026 13:41(KST) Yuhan Corporation has disclosed the clinical phase 1/2 trial design and the current progress for its oral HER2-targeted therapy candidate, YH42946. The company plans to secure initial clinical results by the end of this year, determine the recommended dose,…...

The National Law Review
natlawreview.com > press-releases > definium-therapeutics-discuss-topline-results-phase-3-panorama-study

Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026

10+ hour, 51+ min ago   (484+ words) Definium Therapeutics to Discuss Topline Results from Phase 3 Pan The National Law Review Definium Therapeutics to Discuss Topline Results from Phase 3 Panorama Study in Generalized Anxiety Disorder on September 14, 2026 Company to host webcast tomorrow at 8:00 a.m. EDT NEW YORK--(BUSINESS WIRE)…...